Copernicus Diagnosticssp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2007-03-06
Share capital
50 000,00 PLN
Activity description

Copernicus Diagnostics is a resource intended exclusively for authorized healthcare entities and people with appropriate healthcare qualifications. Its intended users include physicians, laboratory diagnosticians, veterinarians, and administrative employees of healthcare providers.

Registered address
Wileńska 51B/106, 05-200 Wołomin, Poland
Phone
Electronic delivery address
AE:PL-60017-10656-DVVSE-18

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 42 days early. 1 of 6 audited by a statutory auditor.

  • 202506/07/2026
  • 202410/07/2025
  • 202317/06/2024
  • 202201/06/2023
  • 202126/04/2022
  • 202023/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 3.15mMedianUSD 1.06mAverageUSD 22.41m
Net profit
This companyUSD 69.64kMedianUSD 37.20kAverageUSD 879.46k
Operating costs
This companyUSD 3.05mMedianUSD 921.66kAverageUSD 21.08m
Assets
This companyUSD 1.40mMedianUSD 609.79kAverageUSD 11.85m

Website technology

Payments
  • Przelewy24

Public procurement

78 tenders recorded as contractor: 41 national ($1,270,447) and 37 EU ($4,577,089).

SubjectAmount
Supply of tests and consumables for the HLA Immunogenetics Laboratory
$208K
Supply: DaraEX reagent
–
Laboratory reagents together with equipment rental, 7 lots
$66,883

Authorized Representatives

Katarzyna Ciepielowska Ryło – Attorney-in-fact (sole)
Tomasz Marcin Ciepielowski – Vice President of the Management Board
Szymon Dębicki – President of the Management Board

Manner of representation

To represent the company (to make declarations on behalf of the company), the following are authorised: a) the President of the Management Board acting independently; b) each Vice-President acting independently; c) two members of the management board other than the President of the Management Board or the Vice-President acting jointly; d) a member of the management board other than the President of the Management Board or the Vice-President acting jointly with a commercial proxy, where that commercial proxy has been granted joint commercial procuration.

Ownership

OwnerSharesShare valueStake
Tomasz Marcin Ciepielowskiage 75
75$10,129.6675%
Szymon Dębickiage 43
25$3,376.5525%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2012-01-01.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$8,741
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$6,577
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$7,516

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
PromedS.A.
Meditechsp. z o.o.
Move-Xsp. z o.o.
Cambridge Diagnostics (Polska)sp. z o.o.
Model MedicalS.A.
Medical Radiopharmasp. z o.o.
END Corrsp. z o.o.
Medcellsp. z o.o.

Change history

DateEvent
2024-05-07Address change
2016-11-04PKD change
2010-08-19Address change
2010-08-19PKD change
2008-02-28Address change

FAQ

Last updated: 2026-10-07